Asthma
Conditions
Keywords
QMF149, mometasone furoate, indacaterol, pediatric, asthma, PK
Brief summary
This clinical study was designed to assess the pharmacokinetics, safety and tolerability of single inhaled doses of mometasone furoate (MF) when administered alone via MF Twisthaler® (TH) or as an indacaterol acetate/MF fixed dose combination (QMF149) via the Concept 1 (C1) device in pediatric asthma patients.
Detailed description
This study was an open-label, two-period, single-sequence crossover study that consisted of four distinct study periods: * Screening: Participants underwent a screening period of up to 14 days where were assessed for eligibility. * First Treatment: On the first treatment visit (Day 1) participants received a single inhaled dose of 100 μg MF administered via the TH device followed by a 4-7-day washout period. * Second Treatment: On the second treatment visit (Day 6-9) participants received a single inhaled dose of 75/40 μg indacaterol acetate/MF fixed dose combination (FDC) (QMF149) via C1 (Breezhaler®) device. Participants were allowed to use rescue medication (as needed) and potentially their Standard of Care (SoC) asthma therapy (excluding MF and indacaterol acetate). * Safety Follow-up: Upon completion of the treatment period, participants were followed up for safety assessments for 30 days.
Interventions
DRUGMometasone furoate
Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
DRUGQMF149
Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
DRUGStandard of Care (Soc)
Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open label
Intervention model description
Single-sequence crossover study
Eligibility
Sex/Gender
ALL
Age
6 Years to 11 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female children ≥ 6 years and \< 12 years at the time of study entry. 2. Written informed consent by parent(s)/legal guardian(s) for the pediatric patient and assent by the pediatric patient (depending on local requirements) must be obtained before any study-specific assessment is performed. 3. Confirmed documented diagnosis of asthma, as defined by national or international asthma guidelines for at least 6 months prior to study enrollment. 4. Patients using low dose ICS as asthma controller therapy for at least 4 weeks prior to first treatment. 5. Patients who are familiar with the use of an inhaler device. 6. Patients must be able to comply with the Study Visit Assessment Schedule which includes approximately 7 hours on two occasions, and agree to blood draws as scheduled. 7. Parents/ legal guardian must be willing and able to attend study visits and assist the child with the procedures outlined in the protocol
Exclusion criteria
1. Use of other investigational drugs within 5 half-lives of enrollment, or \[within 30 days (for small molecules) /until the expected PD effect has returned to baseline (for biologics)\], whichever is longer. 2. Patients with weight \< 17kg at screening. 3. Patients currently taking MF products for any reason at least 7 days prior to Day 1. Patients can enroll if MF was discontinued at least 7 days prior to Day 1 and MF is substituted with a different steroid during entire study duration to avoid its potential impact on PK assessment. These MF products include inhalation, topical and/or nasal spray formulations. 4. Patients on medium- and high- dose ICS or any dose ICS/LABA combination. 5. Patients taking maintenance controller therapy (eg LABAs and theophylline) within 4 weeks of screening or during the study. LTRAs are permitted provided that patients have been on a stable dose for 4 weeks prior to screening. Patients using short-acting bronchodilators on occasional basis as rescue medication can enroll, however, these medications must be withheld at least 8 hours prior to study dosing visits and during PK sampling. 6. Contraindicated for treatment with, or having a history of reactions/hypersensitivity to any of the following inhaled drugs, drugs of a similar class, or any component there of: * Adrenoreceptor agonist agent Lactose or any of the other excipients of the study drug (including patients with history of galactose intolerance, lactase deficiency or glucose-galactose malabsorption) * Corticosteroids * Indacaterol and/or MF 7. History of chronic lung disease other than asthma within 3 months of first treatment visit (Day 1), cystic fibrosis, mycobacterial or other infection (including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease). 8. History of active bacterial, viral or fungal infection (including SARS-CoV-2) within 6 weeks of first treatment visit (Day 1). 9. Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of first treatment visit (Day 1). 10. Patients who, in the opinion of the investigator, are not able to comply with study treatment or who have any medical or mental disorder, situation, or diagnosis, which could interfere with the proper completion of the study protocol requirements or pose a safety risk while participating in the study. 11. Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g. inability to read, comprehend and write) which will limit the validity of consent for their child to participate in this study. 12. Hemoglobin levels outside normal ranges at screening. 13. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the patient in case of participation in the study. 14. Patients who have a clinically significant ECG abnormality or clinically significant abnormal lab values reported at Screening Visit. 15. Patients with a history of long QT syndrome or whose corrected QT interval (QTc) measured at Screening Visit (Fridericia method) is prolonged (≥ 450 msec for males and females 6 - 12 years old). 16. Use of any prescription drugs, herbal supplements, prescribed medicinal use of cannabis/marijuana, within four weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements within two weeks prior to initial dosing. If needed, (i.e. an incidental and limited need) paracetamol/acetaminophen is acceptable, but must be documented in the Concomitant medications / Significant non-drug therapies page of the CRF. 17. History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 18. Patient is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator. 19. Pregnant or nursing (lactating) females. 20. Inability to properly train in the use of the In-Check DIAL® at screening (at the investigator's discretion). 21. Inability to properly train in the use of the Twisthaler® or Concept 1 Breezhaler® prior to dosing (at the investigator's discretion). 22. History of paradoxical bronchospasm in response to inhaled medicines. 23. Patients receiving any medications in the classes specified in protocol Table 6-2 unless they undergo the required washout period prior to Day 1. 24. Patients who are sexually active.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Mometasone Furoate Plasma Concentration (Cmax) | pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6-9 | Mometasone furoate plasma concentrations were determined by a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. Cmax of mometasone furoate was determined with Phoenix WinNonlin (Version 8.0 or higher). A correction factor was applied to MF pharmacokinetic parameters to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (MF) / FPMunprimed (MF)) for MF delivered via TH was 1.26 and for MF delivered via C1 it was 1.62. |
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time Point 6h (AUC0-6h) of Mometasone Furoate | pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6-9 | AUC0-6h of mometasone furoate was determined using non-compartment methods with Phoenix WinNonlin (Version 8.0 or higher). The linear trapezoidal rule was used for AUC0-6h calculation. A correction factor was applied to MF pharmacokinetic parameters to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (MF) / FPMunprimed (MF)) for MF delivered via TH was 1.26 and for MF delivered via C1 it was 1.62. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systemic Exposure to Indacaterol in Plasma | pre-dose, 0.25 and 1 hour post-dose on Day 6-9 | Systemic exposure to indacaterol in plasma following sparse pharmacokinetic (PK) sampling on Day 6-9 after inhalation of QMF149. A correction factor was applied to indacaterol plasma concentrations to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (indacaterol) / FPMunprimed (indacaterol)) for indacaterol delivered via C1 was 2.0. |
Countries
Hungary, South Africa
Participant flow
Recruitment details
Participants were recruited from 3 sites in 2 countries
Pre-assignment details
Participants underwent a Screening period of up to 14 days
Participants by arm
| Arm | Count |
|---|---|
| MF Followed by QMF149 Single inhaled dose of mometasone furoate on Day 1 delivered via TH inhaler followed by 4-7 days of washout. On Day 6-9, single inhaled dose of QMF149 delivered via C1 inhaler. | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | MF Followed by QMF149 |
|---|---|
| Age, Continuous | 9.0 Years STANDARD_DEVIATION 1.46 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 15 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 24 | 0 / 24 | 0 / 24 |
| other Total, other adverse events | 3 / 24 | 0 / 24 | 3 / 24 |
| serious Total, serious adverse events | 0 / 24 | 0 / 24 | 0 / 24 |
Outcome results
Primary
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time Point 6h (AUC0-6h) of Mometasone Furoate
AUC0-6h of mometasone furoate was determined using non-compartment methods with Phoenix WinNonlin (Version 8.0 or higher). The linear trapezoidal rule was used for AUC0-6h calculation. A correction factor was applied to MF pharmacokinetic parameters to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (MF) / FPMunprimed (MF)) for MF delivered via TH was 1.26 and for MF delivered via C1 it was 1.62.
Time frame: pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6-9
Population: The overall number of participants analyzed includes all participants with evaluable data for the endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MF 100 ug Via Twisthaler | Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time Point 6h (AUC0-6h) of Mometasone Furoate | 208 h*pg/mL | Standard Deviation 102 |
| QMF149 75/40 ug Via Concept 1 | Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time Point 6h (AUC0-6h) of Mometasone Furoate | 176 h*pg/mL | Standard Deviation 57.5 |
Primary
Maximum Observed Mometasone Furoate Plasma Concentration (Cmax)
Mometasone furoate plasma concentrations were determined by a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. Cmax of mometasone furoate was determined with Phoenix WinNonlin (Version 8.0 or higher). A correction factor was applied to MF pharmacokinetic parameters to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (MF) / FPMunprimed (MF)) for MF delivered via TH was 1.26 and for MF delivered via C1 it was 1.62.
Time frame: pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6-9
Population: The overall number of participants analyzed includes all participants with evaluable data for the endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MF 100 ug Via Twisthaler | Maximum Observed Mometasone Furoate Plasma Concentration (Cmax) | 51.9 pg/mL | Standard Deviation 23.5 |
| QMF149 75/40 ug Via Concept 1 | Maximum Observed Mometasone Furoate Plasma Concentration (Cmax) | 53.5 pg/mL | Standard Deviation 16 |
Secondary
Systemic Exposure to Indacaterol in Plasma
Systemic exposure to indacaterol in plasma following sparse pharmacokinetic (PK) sampling on Day 6-9 after inhalation of QMF149. A correction factor was applied to indacaterol plasma concentrations to consider the first-dose effect that is based on the fact that the participants in this study received a single dose from single unused (unprimed) C1 and TH devices. Unprimed devices are not coated with the formulation, and therefore may lead to lower fine particle mass (FPM) and delivered dose compared to later doses actuated from the device throughout its use time. The first-dose correction factor (FPMprimed (indacaterol) / FPMunprimed (indacaterol)) for indacaterol delivered via C1 was 2.0.
Time frame: pre-dose, 0.25 and 1 hour post-dose on Day 6-9
Population: The overall number of participants analyzed includes all participants. The number analyzed per row represents participants with evaluable data at each time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MF 100 ug Via Twisthaler | Systemic Exposure to Indacaterol in Plasma | Pre-dose | 0 pg/mL | Standard Deviation 0 |
| MF 100 ug Via Twisthaler | Systemic Exposure to Indacaterol in Plasma | 0.25 hours post-dose | 102.0 pg/mL | Standard Deviation 54.9 |
| MF 100 ug Via Twisthaler | Systemic Exposure to Indacaterol in Plasma | 1 hours post-dose | 62.3 pg/mL | Standard Deviation 26.2 |